Results 11 to 20 of about 2,285,787 (260)

Chimeric Antigen Receptor beyond CAR-T Cells [PDF]

Cancers, 2021
Chimeric antigen receptors (CAR) are genetically engineered receptors that can recognise specific antigens and subsequently activate downstream signalling. Human T cells engineered to express a CAR, also known as CAR-T cells, can target a specific tumour
D’souza, C, Neeson, PJ, Paul J. Neeson, Zhu, JJ, Criselle D’Souza, Vicky Mengfei Qin, Qin, VM, Joe Jiang Zhu   +7 more
core   +5 more sources

Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T) [PDF]

Mediterranean Journal of Hematology and Infectious Diseases, 2021
Chimeric antigen receptor (CAR) T cells represent one of the newest frontiers of cell therapy. Their application currently involves relapsed/refractory aggressive B cell lymphoma and leukemia as a standard of care, while several studies are exploring CAR-
Hohaus, Stefan, Nicola Piccirillo, Simona Sica, Sica, Simona, Gina Zini, Bellesi, Silvia, Marcello Viscovo, Viscovo, Marcello, Sora, Federica, Galli, Eugenio, Eugenio Galli, Federica Sorà, Patrizia Chiusolo, Laurenti, Luca, De Stefano, Valerio, Luca Laurenti, Chiusolo, Patrizia, Stefan Hohaus, Piccirillo, Nicola, Valerio De Stefano, Silvia Bellesi, Zini, Gina   +21 more
core   +6 more sources

Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells [PDF]

International Journal of Molecular Sciences, 2019
Effective adoptive T cell therapy (ACT) comprises the killing of cancer cells through the therapeutic use of transferred T cells. One of the main ACT approaches is chimeric antigen receptor (CAR) T cell therapy. CAR T cells mediate MHC-unrestricted tumor
Bruno Loureiro Cadilha, Sebastian Kobold, Stefanie Lesch, Mohamed-Reda Benmebarek, Clara Helke Karches, Stefan Endres   +5 more
core   +3 more sources

Chimeric antigen receptor T cell therapy for multiple myeloma

Inflammation and Regeneration, 2019
Chimeric antigen receptor (CAR) T cell therapy is a new cancer immunotherapy targeting cancer-specific cell surface antigen. CD19-CAR T cells have been already shown to be very effective to B cell leukemia/lymphoma.
Kana Hasegawa, Naoki Hosen
doaj   +2 more sources

Genome Editing as a Vehicle to Drive Successful Chimeric Antigen Receptor T Cell Therapies to the Clinic [PDF]

, 2021
Chimeric antigen receptor (CAR) T cells have emerged as an effective therapy for patients with relapsed and refractory haematological malignancies. However, there are many challenges preventing clinical efficacy and thus broader translation of this ...
Caitlin R Hopkins, Joseph A Fraietta
core   +1 more source

BIT-ZJ/Chimeric-antigen-receptor-CAR--T-algorithm: Chimeric antigen receptor (CAR)-T algorithm-v1.0.0

, 2023
This is the first ...
BIT-ZJ
core   +1 more source

Rejection of Experimental Hodgkins Lymphoma by T-cells Engineered with a CD19 Chimeric Antigen Receptor [PDF]

, 2012
T cells engineered to express chimeric receptors combining an external antibody binding domain with the CD3ζ T cell receptor (TCR) internal domain for triggering cell activation are being used for immunotherapeutic targeting of tumour cells in a non-HLA ...
Cheadle, Eleanor, Johannessen, Ingolfur, Talbot, Simon, Cheadle, Eleanor J, Crawford, Dorothy, Gilham, David, Gilham, David E, Johannessen, Ingo, Swanson, Anna   +8 more
core   +1 more source

Classic and Activating Chimeric Antigen Receptors PD-1 as an Element of Multi-Target Approach to the Treatment of Hematological and Solid Neoplasms

Клиническая онкогематология, 2023
Aim. To generate anti-PD-L1 CAR-T effectors carrying extracellular domain PD-1 as antigen-recognizing site and to study their cytolytic activity as well as to functionally assess the anti-PD-L1 CAR-T effectors in vitro with a view to apply them in multi ...
Kseniya Aleksandrovna Levchuk, A. A. Goldaev, E. A. Stolyarova, P. A. Mateikovich, A. Kh. Valiullina, E. R. Bulatov, A. V. Petukhov, A. A. Daks, N. A. Barlev, E. V. Baidyuk, Ya. G. Toropova   +10 more
doaj   +1 more source

Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axis

Nature Communications, 2022
Co-expression of PD-L1-specific chimeric switch receptors (CSRs) improves the antitumor effects of chimeric antigen receptor (CAR) T cells. Here, CSRs are shown to promote the differentiation of mesothelin-targeting CAR T cells into central memory-like ...
Le Qin, Yuanbin Cui, Tingjie Yuan, Dongmei Chen, Ruocong Zhao, Shanglin Li, Zhiwu Jiang, Qiting Wu, Youguo Long, Suna Wang, Zhaoyang Tang, Huixia Pan, Xiaoping Li, Wei Wei, Jie Yang, Xuequn Luo, Zhenfeng Zhang, Qiannan Tang, Pentao Liu, Robert Weinkove, Yao Yao, Dajiang Qin, Jean Paul Thiery, Peng Li   +23 more
doaj   +1 more source

Combinatorial functions of two chimeric antibodies directed to human CD4 and one directed to the a-chain of the human interleukin-2 receptor [PDF]

, 1992
The general feasibility of chimerization of monoclonal antibodies (mAbs) has already been shown for a large number of them. In order to evaluate in vitro parameters relevant to immunosuppressive therapy, we have chimerized and synthesized two anti-CD4 ...
Schwirzke, Marina, Kaluzab, Brigitte, Reiter, Christian, Rieber, Ernst Peter, Scheuer, Werner, Flieger, Dimitri, Lenz, Helmut, Weissenhorn, Winfried, Weiss, Elisabeth H., Weidle, Ulrich H., Riethmüller, Gert   +10 more
core   +1 more source